Granted Patent
B2
US 12,201,685 · App. 17/061,464 · Granted Jan 21, 2025
Methods of modulating immune responses with cationic lipid vaccine compositions
Inventors:
Kenya Johnson (Mason, OH); Eric Jacobson (Cincinnati, OH); Frank Bedu-Addo (Bethel, CT); Mikayel Mkrtichyan (Rockville, MD); Samir N. Khleif (Silver Spring, MD)
Assignees:
PDS Biotechnology Corporation; The United States of America as Represented by the Secretary of the Department of Health and Human Services
A61K39/39A61K39/0005A61K39/0011A61K39/12A61K2039/55511A61K2039/55516A61K2039/55522A61K2039/55555A61K2039/55566A61K2039/585C12N2710/20034
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor. The disclosure also provides methods of reducing an immune suppressor cell population in a mammal, methods of argumenting an immune response in a mammal, and methods of treating a diseases in a mammal utilizing the vaccine compositions.
Claims (18)
1. A method of reducing an immune suppressor cell population in a mammal, said method comprising the step of administering an effective amount of a composition to the mammal, wherein the composition comprises an adjuvant and a therapeutic factor, wherein the adjuvant is a cationic lipid and wherein the therapeutic factor is a cytokine selected from interleukins 1-18.
2. The method of claim 1 , wherein the immune suppressor cell is a myeloid-derived suppressor cell (MDSC).
3. The method of claim 1 , wherein the cationic lipid is selected from the group consisting of DOTAP, DOTMA, DOEPC, and combinations thereof.
4. The method of claim 1 , wherein the cationic lipid is DOTAP.
5. The method of claim 1 , wherein the adjuvant is an enantiomer of the cationic lipid.
6. The method of claim 5 , wherein the enantiomer is R-DOTAP.
7. The method of claim 1 , wherein the composition further comprises one or more antigens.
8. The method of claim 7 , wherein the one or more antigens is an HPV protein or peptide.
9. The method of claim 8 , wherein the one or more antigens comprise one or more of the gp100 sequence (KVPRNQDWL [SEQ ID NO: 8]) and the TRP2 sequence (SYVDFFVWL [SEQ ID NO: 9]).
10. A method of augmenting an immune response in a mammal, said method comprising the step of administering an effective amount of a vaccine composition to the mammal, wherein the vaccine composition comprises an adjuvant and a therapeutic factor, wherein the adjuvant is a cationic lipid, and wherein the therapeutic factor is a cytokine selected from interleukins 1-18.
11. The method of claim 10 , wherein the reduction results in an increase in T-cell response in the mammal.
12. The method of claim 11 , wherein the T-cell response is a CD8+ T-cell response.
13. The method of claim 10 , wherein the cationic lipid is selected from the group consisting of DOTAP, DOTMA, DOEPC, and combinations thereof.
14. The method of claim 13 , wherein the cationic lipid is DOTAP.
15. The method of claim 14 , wherein the adjuvant is an enantiomer of the cationic lipid.
16. The method of claim 15 , wherein the enantiomer is R-DOTAP.
17. The method of claim 10 , wherein the composition further comprises one or more antigens.
18. The method of claim 17 , wherein the one or more antigens is an HPV protein or peptide and wherein the antigen comprises one or more of the gp100 sequence (KVPRNQDWL [SEQ ID NO: 8]) and the TRP2 sequence (SYVDFFVWL [SEQ ID NO: 9]).
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 2, 2020
From: JOHNSON, KENYA; BEDU-ADDO, FRANK
To: PDS BIOTECHNOLOGY CORPORATION
Reel/Frame 053958/0403 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 2, 2020
From: JACOBSON, ERIC
To: PDS BIOTECHNOLOGY CORPORATION
Reel/Frame 053958/0476 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 2, 2020
From: KHLEIF, SAMIR N.; MKRTICHYAN, MIKAYEL
To: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 053958/0556 →
Continuity (4)
Division
14407419
Provisional Application
61660172
· Jun 15, 2012
References Cited (400)
US 2167480A
· Hansell
· 1939
[cited by applicant]
US 4703004A
· Hopp et al.
· 1987
[cited by applicant]
US 5264618A
· Felgner et al.
· 1993
[cited by applicant]
US 5283185A
· Epand et al.
· 1994
[cited by applicant]
US 5334761A
· Gebeyehu et al.
· 1994
[cited by applicant]
US 5459127A
· Felgner et al.
· 1995
[cited by applicant]
US 5827703A
· Debs et al.
· 1998
[cited by applicant]
US 6008202A
· Huang et al.
· 1999
[cited by applicant]
US 6124270A
· Haensler
· 2000
[cited by applicant]
US 6183745B1
· Tindle et al.
· 2001
[cited by applicant]
US 6214804B1
· Felgner et al.
· 2001
[cited by applicant]
US 6419931B1
· Vitiello et al.
· 2002
[cited by applicant]
US 6464980B1
· Fikes et al.
· 2002
[cited by applicant]
US 6586409B1
· Wheeler
· 2003
[cited by applicant]
US 6610321B2
· Huang et al.
· 2003
[cited by applicant]
US 6649170B1
· Lindblad et al.
· 2003
[cited by applicant]
US 6693086B1
· Dow et al.
· 2004
[cited by applicant]
US 6710035B2
· Felgner et al.
· 2004
[cited by applicant]
US 6780421B1
· Haensler et al.
· 2004
[cited by applicant]
US 6852334B1
· Cullis et al.
· 2005
[cited by applicant]
US 7001614B2
· Smyth-Templeton et al.
· 2006
[cited by applicant]
US 7105574B1
· Wheeler
· 2006
[cited by applicant]
US 7303881B2
· Huang et al.
· 2007
[cited by applicant]
US 7488791B2
· Maillere et al.
· 2009
[cited by applicant]
US 8877206B2
· Chen et al.
· 2014
[cited by applicant]
US 9102950B2
· Hartikka et al.
· 2015
[cited by applicant]
US 9789129B2
· Vasievich et al.
· 2017
[cited by applicant]
US 20010026937A1
· Punnonen et al.
· 2001
[cited by applicant]
US 20020187105A1
· Zou et al.
· 2002
[cited by applicant]
US 20030008813A1
· Felgner et al.
· 2003
[cited by applicant]
US 20030229040A1
· Kasid et al.
· 2003
[cited by applicant]
US 20040157791A1
· Dow et al.
· 2004
[cited by applicant]
US 20040185057A1
· Kirkby et al.
· 2004
[cited by applicant]
US 20050025822A1
· Wong et al.
· 2005
[cited by applicant]
US 20050112559A1
· Leung et al.
· 2005
[cited by applicant]
US 20050176672A1
· Scheule et al.
· 2005
[cited by applicant]
US 20060051405A1
· MacLachlan et al.
· 2006
[cited by applicant]
US 20060159738A1
· Graham et al.
· 2006
[cited by applicant]
US 20060165708A1
· Mayumi et al.
· 2006
[cited by applicant]
US 20060182793A1
· Bachmann et al.
· 2006
[cited by applicant]
US 20060275777A1
· Waelti
· 2006
[cited by applicant]
US 20060286124A1
· Burt et al.
· 2006
[cited by applicant]
US 20070014807A1
· Maida, III
· 2007
[cited by applicant]
US 20070059318A1
· Balu-Iyer et al.
· 2007
[cited by applicant]
US 20070066552A1
· Clarke
· 2007
[cited by applicant]
US 20080014251A1
· Benz et al.
· 2008
[cited by applicant]
US 20080131455A1
· Huang et al.
· 2008
[cited by applicant]
US 20080248044A1
· Choppin et al.
· 2008
[cited by applicant]
US 20100086584A1
· Callejo et al.
· 2010
[cited by applicant]
US 20100099745A1
· Sambhara et al.
· 2010
[cited by applicant]
US 20100189742A1
· Van Der Burg et al.
· 2010
[cited by applicant]
US 20100203080A1
· Maillere et al.
· 2010
[cited by applicant]
US 20100221223A1
· Tsutsui et al.
· 2010
[cited by applicant]
US 20110158952A1
· Beach et al.
· 2011
[cited by applicant]
US 20110305713A1
· Munn et al.
· 2011
[cited by applicant]
US 20150079155A1
· Jensen et al.
· 2015
[cited by applicant]
US 20150110823A1
· Bedu-Addo et al.
· 2015
[cited by applicant]
US 20150250872A1
· Bedu-Addo et al.
· 2015
[cited by applicant]
US 20160168227A1
· Kallen et al.
· 2016
[cited by applicant]
US 20160193316A1
· Sette et al.
· 2016
[cited by applicant]
US 20170296639A1
· Ma et al.
· 2017
[cited by applicant]
US 20180221475A1
· Bedu-Addo et al.
· 2018
[cited by applicant]
CN 1909918A
· 2007
[cited by applicant]
CN 101027317A
· 2007
[cited by applicant]
CN 101065350A
· 2007
[cited by applicant]
CN 101193655A
· 2008
[cited by applicant]
CN 101702882A
· 2010
[cited by applicant]
CN 102137675A
· 2011
[cited by applicant]
CN 104189897A
· 2014
[cited by applicant]
CN 104703588A
· 2015
[cited by applicant]
CN 105101991A
· 2015
[cited by applicant]
CN 105163753A
· 2015
[cited by applicant]
CN 105920599A
· 2016
[cited by applicant]
CN 111217918A
· 2020
[cited by applicant]
EP 2167480A2
· 2010
[cited by applicant]
JP H06510051A
· 1994
[cited by applicant]
JP H09502086A
· 1997
[cited by applicant]
JP H10501822A
· 1998
[cited by applicant]
JP 2002537102A
· 2002
[cited by applicant]
JP 2002542341A
· 2002
[cited by applicant]
JP 2003506095A
· 2003
[cited by applicant]
JP 2003509035A
· 2003
[cited by applicant]
JP 2004508012A
· 2004
[cited by applicant]
JP 2006513979A
· 2006
[cited by applicant]
JP 2006527762A
· 2006
[cited by applicant]
JP 2007238559A
· 2007
[cited by applicant]
JP 2008521757A
· 2008
[cited by applicant]
JP 2010522206A
· 2010
[cited by applicant]
JP 2010537961A
· 2010
[cited by applicant]
JP 2011518170A
· 2011
[cited by applicant]
JP 2012526853A
· 2012
[cited by applicant]
JP 2014527965A
· 2014
[cited by applicant]
JP 2015521601A
· 2015
[cited by applicant]
JP 2015530413A
· 2015
[cited by applicant]
KR 20150058139A
· 2015
[cited by applicant]
RU 2311911C2
· 2007
[cited by applicant]
TW 200902060A
· 2009
[cited by applicant]
TW 201000124A
· 2010
[cited by applicant]
TW I589298
· 2014
[cited by applicant]
WO WO9303709A1
· 1993
[cited by applicant]
WO WO9303764A1
· 1993
[cited by applicant]
WO 9322338
· 1993
[cited by applicant]
WO WO9504542A1
· 1995
[cited by applicant]
WO WO9527508A1
· 1995
[cited by applicant]
WO WO9703703A1
· 1997
[cited by applicant]
WO WO0050006A2
· 2000
[cited by applicant]
WO WO0062813A2
· 2000
[cited by applicant]
WO 0077043A2
· 2000
[cited by applicant]
WO WO0111067A1
· 2001
[cited by applicant]
WO WO0119408A1
· 2001
[cited by applicant]
WO WO0157068A1
· 2001
[cited by applicant]
WO WO0180900A2
· 2001
[cited by applicant]
WO WO02069369A2
· 2002
[cited by applicant]
WO WO02097116A2
· 2002
[cited by applicant]
WO WO03000398A2
· 2003
[cited by applicant]
WO WO03003985A2
· 2003
[cited by applicant]
WO WO03011252A1
· 2003
[cited by applicant]
WO WO03095641A1
· 2003
[cited by applicant]
WO WO2004014957A1
· 2004
[cited by applicant]
WO WO2004089413A1
· 2004
[cited by applicant]
WO WO2005000889A1
· 2005
[cited by applicant]
WO 2006063382
· 2006
[cited by applicant]
WO WO2007022152A2
· 2007
[cited by applicant]
WO WO2007121895A2
· 2007
[cited by applicant]
WO WO2008116078A2
· 2008
[cited by applicant]
WO 2008148057A2
· 2008
[cited by applicant]
WO 2009129227
· 2009
[cited by applicant]
WO WO2008116078A4
· 2009
[cited by applicant]
WO WO2009142892A1
· 2009
[cited by applicant]
WO 2010101663
· 2010
[cited by applicant]
WO WO2011083820A1
· 2011
[cited by applicant]
WO WO2013016675A1
· 2013
[cited by applicant]
WO WO2013188627A2
· 2013
[cited by applicant]
WO WO2014047533A1
· 2014
[cited by applicant]
WO WO2015061416A2
· 2015
[cited by applicant]
WO WO2015176662A1
· 2015
[cited by applicant]
WO WO2016146618A1
· 2016
[cited by applicant]
WO WO2017083820A1
· 2017
[cited by applicant]
Taiwanese Office Action dated Jun. 20, 2016, from counterpart Taiwanese Application No. 102121266, along with an English Translation of the Search Report.
[cited by applicant]
Supplementary European Search Report dated Jan. 22, 2016, from counterpart European Appln. No. 13804165.2.
[cited by applicant]
Office Action from counterpart Taiwanese Patent Appln. No. 106109798 and its English translation; mail dated Nov. 14, 2017.
[cited by applicant]
Dranoff G., GM-CSF based vaccines, Immunol. Rev. 188, 147-154, 2002.
[cited by applicant]
Office Action for counterpart Russian Application No. 2015101110 along with its English translation; mail dated Aug. 8, 2017.
[cited by applicant]
Office Action for counterpart Russian Application No. 2015101110 along with its English translation; mail dated Mar. 28, 2017.
[cited by applicant]
Sinha et al. (2007) Cross-Talk between Myeloid-Derived Suppressor Cells and Macrophages Subverts Tumor Immunity toward a Type 2 Response, J. Immunol. 179:977-983.
[cited by applicant]
Gabrilovich et al. (2009) Myeloid-derived-suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9(3): 162-174 (pp. 1-26 NIH Manuscript).
[cited by applicant]
First Examination Report from counterpart Indian Appln. No. 11144/DELNP/2014 dated Mar. 7, 2019.
[cited by applicant]
Perales et al., “Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma”,
[cited by applicant]
Vasievich et al., “Trp2 peptide vaccine adjuvanted with ®-DOTAP inhibits tumor growth in an advanced melanoma model”,
[cited by applicant]
Extended European Search Report from counterpart European Application No. 19203293.6 dated Mar. 10, 2020.
[cited by applicant]
Berraondo, Pedro et al., “Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system”,
[cited by applicant]
Vangasseri, Dileep P. et al., “Immunostimulation of dendritic cells by cationic liposomes”,
[cited by applicant]
“3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-ethoxy-N, N, N-trimethyl-10-oxo-7-[[(9Z)-1-oxo-9-octadecen-1-yl]oxy]-, 4-oxide, (7R, 18Z)-,” Registry, Chemical Abstracts Service, Columbus, Ohio, US, Database Accessio…
[cited by applicant]
Alving C.R., “Design And Selection Of Vaccine Adjuvants: Animal Models And Human Trials,” Vaccine, Elsevier Science Ltd, 2002, vol. 20, pp. S56-S64.
[cited by applicant]
Anderson P., “Effective Vaccination of Mice Against Mycobacterium Tuberculosis Infection With A Soluble Mixture of Secreted Mycobacterial Proteins,” Infection and Immunity, American Society for Microbiology, Jun. 1994, …
[cited by applicant]
Aramaki Y., et al., “Induction of Apoptosis in WEHI 231 Cells by Cationic Liposomes,” Pharmaceutical Research, Plenum Publishing Corporation, Jan. 18, 2000, vol. 17, No. 5, pp. 515-520.
[cited by applicant]
Baecher-Allan C., et al., “Immune Regulation In Tumor-Bearing Hosts,” Current Opinion In Immunology, Elsevier Limited, 2006, vol. 18, pp. 214-219.
[cited by applicant]
Baecher-Allan C., et al., “Suppressor T Cells in Human Diseases,” Journal of Experimental Medicine, The Rockefeller University Press, Aug. 2, 2004, vol. 200, No. 3, pp. 273-276.
[cited by applicant]
Banchereau J., et al., “Dendritic Cells And The Control of Immunity,” Nature, Mar. 19, 1998, vol. 392, No. 6673, pp. 245-252.
[cited by applicant]
Bei R., et al., “The Use of a Cationic Liposome Formulation (DOTAP) Mixed with a Recombinant Tumor-Associated Antigen to Induce Immune Responses and Protective Immunity in Mice,” Journal of Immunotherapy, 1998, vol. 21,…
[cited by applicant]
Bei R., et al., “The Use of a Cationic Liposome Formulation (DOTAP) Mixed With a Recombinant Tumor-associated Antigen to Induce Immune Responses and Protective Immunity in Mice,” Journal Of Immunotherapy, Lippincott Wil…
[cited by applicant]
Benmohamed L., et al., Lipopetide Immunization Without Adjuvant Induces Potent And Long-Lasting B, T Helper, And Cytotoxic T Lymphocyte Resonses Against A Malaria Liver Stage Antigen In Mice And Chimpanzees, European Jo…
[cited by applicant]
Black M., et al., “Advances In The Design And Delivery Of Peptide Subunit Vaccines With A Focus On Toll-like Receptor Agonists.” Expert Rev. Vaccines, vol. 9, No. 2, 2010, pp. 157-173.
[cited by applicant]
Brunel F., et al., “Cationic Lipid DC-Chol Induces an Improved and Balanced Immunity Able to Overcome the Unresponsiveness to the Hepatitis B Vaccine,” Vaccine, Apr. 1999, vol. 17, pp. 2192-2203.
[cited by applicant]
Brunette E., et al., “Lipofection Does Not Require the Removal of Serum,” Nucleic Acids Research, Cancer Research Institute, University Of California San Francisco Medical Center, San Francisco, California, Dec. 26, 199…
[cited by applicant]
Byers A.M., et al., “Cutting Edge: Rapid In Vivo CTL Activity by Polyoma Virus-Specific Effector and Memory CD8+ T Cells,” The American Association of Immunologists Inc., The Journal of Immunology, 2003, vol. 171, pp. 1…
[cited by applicant]
Cantor H., et al., “Immunoregulatory Circuits Among T-Cell Sets II. Physiologic Role of Feedback Inhibition in Vivo: Absence in NZB Mice,” The Rockefeller University Press, Journal of Experimental Medicine, 1978, pp. 11…
[cited by applicant]
Carr M.W., et al., “Monocyte Chemoattractant Protein 1 Acts As AT-Lymphocyte Chemoattractant,” Proceedings Of The National Academy Of Sciences of The United States Of America, Committee On Immunology and Department Of P…
[cited by applicant]
Castellino F., et al., “Chemokine-Guided CD4+ T Cell Help Enhances Generation Of IL-6Ra high IL-7Ra high Prememory COB+ T Cells,” The Journal Of Immunology, Lymphocyte Biology Section, Laboratory Of Immunology, National…
[cited by applicant]
Castellino F., et al., “Chemokines Enhance Immunity By Guiding Naive COB+ T Cells To Sites Of CD4+ T Cell-Dendritic Cell Interaction,” Nature, Lymphocyte Biology Section, Laboratory Of Immunology, National Institute Of …
[cited by applicant]
Chen W., et al., “A Simple and Effective Cancer Vaccine Consisting of an Antigen and a Cationic Lipid,” Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Chapel Hill, Chapel Hill, No…
[cited by applicant]
Chen W., et al., “A Simple But Effective Cancer Vaccine Consisting Of An Antigen And A Cationic Lipid,” Cancer Immunology, Immunotherapy, Springer, Berlin, DE, Aug. 28, 2007, vol. 57, No. 4, pp. 517-530, ISSN 1432-0851,…
[cited by applicant]
Chen W., et al., “Induction of Cytotoxic T-Lymphocytes and Antitumor Activity by a Liposomal Lipopeptide Vaccine,” Molecular Pharmaceutics, 2008, vol. 5, No. 3, pp. 464-471.
[cited by applicant]
Chen W.C., et al., “Cationic Liposome-Based Peptide Vaccine: Potent Therapeutics for Cervical Cancer,” Poster, School of Pharmacy, May 20, 2006, 1 Page.
[cited by applicant]
Chikh G., et al., “Liposomal Delivery of CTL Epitopes to Dendritic Cells, Bioscience Reports,” Plenum Publishing Corporation, Apr. 2002, vol. 22, No. 2, pp. 339-353.
[cited by applicant]
Christensen D., et al., “Cationic Liposomes as Vaccine Adjuvants,” Expert Review of Vaccines, Oct. 2007, vol. 6, No. 5, pp. 785-796, XP008137314.
[cited by applicant]
Cohen P.A., et al., “CD4+ T-Cells From Mice Immunized To Syngeneic Sarcomas Recognize Distinct, Non-Shared Tumor Antigens,” Cancer Research, Branches Of Surgery And Dermatology, National Cancer Institute, National Insti…
[cited by applicant]
Comes A., et al., “CD25+ Regulatory T Cell Depletion Augments Immunotherapy of MicroMetastases by an IL-21-Secreting Cellular Vaccine1,” The Journal of Immunology, The American Association of Immunologists Incorporated,…
[cited by applicant]
Communication about Intention to Grant a European Patent received for European Application No. 08799629.4, mailed on Jun. 1, 2015, 6 Pages.
[cited by applicant]
Communication about Intention to Grant a European Patent Received for European Application No. 09733034.4, mailed on Jul. 6, 2018, 6 Pages.
[cited by applicant]
Communication about Intention to Grant a European Patent Received for European Application No. 12831495.2, mailed on Feb. 16, 2018, 10 Pages.
[cited by applicant]
Communication about Intention to Grant a European Patent Received for European Application No. 13804165.2, mailed on May 9, 2019, 7 Pages.
[cited by applicant]
Connor J., et al., “pH-Sensitive Immunoliposomes as an Efficient and Target-Specific Carrier for Antitumor Drugs,” Cancer Research, Department of Biochemistry, University of Tennessee, KnoxvilleTennessee, Jul. 1986, vol…
[cited by applicant]
Copland M.J., et al., “Lipid Based Particulate Formulations for the Delivery of Antigen,” Immunology and Cell Biology, Australasian Society for Immunology Incorporate, 2005, vol. 83, pp. 97-105.
[cited by applicant]
Credo Reference, 2005.
[cited by applicant]
Cui Z., et al., “Coating of Mannan on LPD Particles Containing HPV E7 Peptide Significantly Enhances Immunity Against HPV-Positive Tumor,” Pharmaceutical Research, Jun. 2004, vol. 21, No. 6, pp. 1018-1025.
[cited by applicant]
Cui Z., et al., “Immunostimulation Mechanism of LPD Nanoparticle as a Vaccine Carrier,” Molecular Pharmaceutics, American Chemical Society, 2005, vol. 2, No. 1, pp. 22-28.
[cited by applicant]
Cui Z., et al., “Liposome-Polycation-DNA (LPD) Particle As A Carrier and Adjuvant for Protein-Based Vaccines: Therapeutic Effect Against Cervical Cancer,” Cancer Immunology and Immunother, Springer-Verlag, 2005, vol. 54…
[cited by applicant]
Datta G., et al., “Effects of Increasing Hydrophobicity on the Physical-Chemical and Biological Properties of a Class A Amphipathic Helical Peptide,” Journal of Lioid Research, 2001, vol. 42, pp. 1096-1104.
[cited by applicant]
Davies G., “Adjuvant Activity of Cytokines,” Chapter 19, Methods in Molecular Biology, 2010, ISSN: 0003658713, pp. 287-309.
[cited by applicant]
De Bruijn M.L.H., et al., “Immunization With Human Papillomavirus Type 16 (Hpv16) Oncoproteinoloaded Dendritic Cells As Well As Proteinin Adjuvant Induces Mhc Class 1-restricted Protection To Hpv16-induced Tumor Cells,”…
[cited by applicant]
Decision of Rejection from Corresponding Japanese Patent Application No. JP2018524752, dated Jul. 13, 2021, 6 Pages.
[cited by applicant]
Decision on the Request for Reexamination from Corresponding Chinese Application No. 200880017151.0, dated Jun. 12, 2017, 18 pages.
[cited by applicant]
Decision to Grant a European Patent received for European Application No. 08799629.4, mailed on Oct. 15, 2015, 3 Pages.
[cited by applicant]
Decision to Grant a European Patent received for European Application No. 09733034.4, mailed on Oct. 25, 2018, 2 Pages.
[cited by applicant]
Decision to Grant a European Patent Received for European Application No. 12831495.2, mailed on Jun. 7, 2018, 2 Pages.
[cited by applicant]
Decision to Grant a European Patent received for European Application No. 13804165.2, mailed on Sep. 19, 2019, 3 Pages.
[cited by applicant]
Decker T., et al., “The Yin and Yang of Type I Interferon Activity in Bacterial Infection,” Nature Reviews Immunology, 2005, vol. 5, pp. 675-687.
[cited by applicant]
Denning D.W., et al., “Micafungin (FK463), Alone or in Combination with Other Systemic Antifungal Agents, for the Treatment of Acute Invasive Aspergillosis,” Journal Of Infection, Elsevier Ltd, 2006, vol. 53, pp. 337-34…
[cited by applicant]
Desilva D.R, et al., “The p38 Mitogen-Activated Protein Kinase Pathway in Activated and Anergic Th1 Cells,” Cellular Immunology, Academic Press, 1997, vol. 180, pp. 116-123.
[cited by applicant]
Diamond D.J., et al., “Development of a Candidate HLA A 0201 Restricted Peptide-Based Vaccine Against Human Cytomegalovirus Infection,” Blood, Sep. 1, 1997, vol. 90, No. 05, pp. 1751-1767.
[cited by applicant]
Dileo J., et al., “Lipid-Protamine-DNA-Mediated Antigen Delivery to Antigen-Presenting Cells Results in Enhanced Anti-Tumor Immune Responses,” The American Society of Gene Therapy, Molecular Therapy, May 2003, vol. 7, N…
[cited by applicant]
Dillon S., et al., “A Toll-Like Receptor 2 Ligand Stimulates Th2 Responses In Vivo, Via Induction Of Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase and c-Fos In Dendritic Cells,” The Journal Of I…
[cited by applicant]
Dolcetti L., et al., “Hierarchy of Immunosuppressive Strength Among Myeloid-derived Suppressor Cell Subsets is determined by GM-CSF,” European Journal of Immunology, 2010, vol. 40, pp. 22-35.
[cited by applicant]
Dong C., et al., “MAP Kinases in the Immune Response,” Annual Review of Immunology, Annual Reviews, 2002, vol. 20, pp. 55-72.
[cited by applicant]
Dow S.W., et al., “Lipid-DNA Complexes Induce Potent Activation of Innate Immune Responses and Antitumor Activity When Administered Intravenously,” The Journal of Immunology, 1999, vol. 163, pp. 1552-1561.
[cited by applicant]
Dupuis M., et al., “Dendritic Cells Internalize Vaccine Adjuvant After Intramuscular Injection,” Cellular Immunology, Academic Press, 1998, vol. 186, pp. 18-27.
[cited by applicant]
Eardley D.D., et al., “Immunoregulatory Circuits Among T-Cell Sets I. T-Helper Cells Induce Other T-Cell Sets to Exert Feedback Inhibition,” The Rockefeller University Press, Journal of Experimental Medicine, 1978, pp. …
[cited by applicant]
EMBL Database Entry GG774706,
[cited by applicant]
English Translation of Chinese First Office Action of Corresponding Chinese Application No. 201380060902.8, dated May 26, 2016, 12 Pages.
[cited by applicant]
English Translation of First Office Action from Corresponding Chinese Application No. 201710819740.1, dated Jul. 17, 2020, 21 Pages.
[cited by applicant]
English Translation of First Office Action in Counterpart Chinese Application No. 201880088575.X, dated Dec. 29, 2021, 21 Pages.
[cited by applicant]
English Translation of Fist Office Action from Corresponding Chinese Patent Application No. 201710819740.1, dated Apr. 29, 2021, 15 Pages.
[cited by applicant]
English Translation of Notice of Reasons for Refusal Received in Corresponding Japanese Patent Application No. 2018-524752 dated Sep. 3, 2020, 8 Pages.
[cited by applicant]
English Translation of Notification of Defects from Corresponding Israel Application No. 259294, dated May 5, 2021, 6 Pages.
[cited by applicant]
English translation of Notification of Reasons for Rejection from Corresponding Japanese Application No. 2014-17712, mailed Sep. 15, 2015, 11 Pages.
[cited by applicant]
English Translation of Office Action from Corresponding Taiwan Application No. 102134251, dated Apr. 24, 2017, 13 Pages.
[cited by applicant]
English Translation of Office Action in Taiwanese Application No. 101133392, mailed Nov. 2, 2015, 16 pages.
[cited by applicant]
English Translation of Office Action Japanese Application No. JP2014529976, mailed Jul. 11, 2017, 07 pages.
[cited by applicant]
English Translation of Third Chinese Office Action from Corresponding Chinese Application No. 201380060902.8, dated Oct. 18, 2017, 27 Pages.
[cited by applicant]
English Translation of Third Office Action from Corresponding Chinese Application No. 200980121761.X, dated May 9, 2016, 10 Pages.
[cited by applicant]
European Communication Corresponding European Application No. EP12831495.2 dated Jun. 6, 2016, 5 pages.
[cited by applicant]
European Search Report and Written Opinion prepared for EP12831495 completed on Mar. 5, 2015, 8 Pages.
[cited by applicant]
Examination Report No. 1 for Corresponding Australian Application No. 2013317805, mailed Jul. 11, 2017, 4 Pages.
[cited by applicant]
Examination Report No. 2 from Corresponding Australian Patent Application No. 2017340407, dated Jan. 6, 2021, 5 Pages.
[cited by applicant]
Extended European Search Report for European Application No. 13804165.2, mailed Jan. 5, 2016, 5 Pages.
[cited by applicant]
Extended European Search Report for European Application No. 13839199.0, mailed Apr. 4, 2016, 7 Pages.
[cited by applicant]
Extended European Search Report for European Application No. 16865201.4, mailed Jun. 6, 2019, 10 Pages.
[cited by applicant]
Extended European Search Report for European Application No. 17859111.1, mailed May 26, 2020, 7 Pages.
[cited by applicant]
Extended European Search Report for European Application No. 18886648.7, mailed Aug. 11, 2021, 9 Pages.
[cited by applicant]
Extended European Search Report for European Application No. 08799629.4, mailed Mar. 5, 2010, 04 Pages.
[cited by applicant]
Extended European Search Report for European Application No. 09733034.4, mailed Apr. 15, 2013, 07 Pages.
[cited by applicant]
Extended European Search Report for European Application No. 12831495.2, mailed Mar. 16, 2015, 09 Pages.
[cited by applicant]
Felnerova D., et al., “Liposomes and Virosomes as Delivery Systems for Antigens,” Nucleic Acids and Drugs, Current Opinion in Biotechnology, Elsevier Ltd, 2004, vol. 15, pp. 518-529.
[cited by applicant]
Feltkamp M.C., et al., “Vaccination with Cytotoxic T Lymphocyte Epitope-containing Peptide Protects Against a Tumor Induced by Human Papillomavirus Type 16-transformed Cells,” European Journal Of Immunology, PubMed, Sep…
[cited by applicant]
Fernandes I., et al., “Synthetic Lipopeptides Incorporated In Liposomes: In Vitro Stimulation OfThe Profliferation Of Murine Splenocytes And In Vivo Induction Of An Immune Response Against A Peptide Antigen,” Molecular …
[cited by applicant]
Filion M.C., et al., “Anti-Inflammatory Activity of Cationic Lipids,” British Journal Of Pharmacology, Oct. 1997, vol. 122, No. 3, pp. 551-557, ISSN 0007-1188, XP002569679.
[cited by applicant]
Filion M.C., “Major Limitations in the Use of Cationic Liposomes for DNA Delivery,” International Journal of Pharmaceutics, 1998, vol. 162, No. 1-2, pp. 159-170.
[cited by applicant]
Final Office Action from Corresponding U.S. Appl. No. 15/775,680, dated Jan. 22, 2021, 9 Pages.
[cited by applicant]
First Examination Report from Corresponding Indian Patent Application No. 201618020440, dated Nov. 10, 2020, 4 Pages.
[cited by applicant]
First Office Action from Corresponding Chinese Patent Application No. 201811312211.3, dated Aug. 3, 2021, 27 Pages.
[cited by applicant]
Fuertes M.B., et al., “Host Type I IFN Signals are Required for Antitumor CD8+ T Cell Responses Through CD8α+ Dendritic Cells,” Journal of Experimental Medicine, 2011, vol. 208, pp. 2005-2016.
[cited by applicant]
Gahery-Segard H., et al., “Multiepitopic B- And T-Cell Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine,” American Society For Microbiology, Journal Of Virology, Feb. 2000, vol. 7…
[cited by applicant]
Gandhapudi S.K., et al., “Antigen Priming With Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses Through Novel Induction Of A Type I IFN Response,” Journal of Immunology, May 3, 2019, v…
[cited by applicant]
Glick D., “Methods of Biochemical Analysis,” Cancer Biology Research Laboratory, Stanford University Medical Center, Stanford, California, 1988, vol. 33, pp. 337-462.
[cited by applicant]
Gluck R., et al., “Biophysical Validation of Epaxal Berna, a Hepatitis A Vaccine Adjuvanted with Immunopotentiating Reconstituted Influenza Virosomes (IRIV),”Developments in Biologicals, 2000, vol. 103, 12 Pages.
[cited by applicant]
Gold J.S., et al. “A Single Heteroclitic Epitope Determines Cancer Immunity After Xenogeneic Dna Immunization Against A Tumor Differentiation Antigen,” The Journal of Immunology, 2003, 170.10, pp. 5188-5194.
[cited by applicant]
Grabowska et al., “Identification of Promiscuous Hpv16-Derived T Helper Cell Epitopes for Therapeutic Hpv Vaccine Design,” International Journal of Cancer, 2015, vol. 136, No. 1, pp. 212-224, XP055497833.
[cited by applicant]
Greenfield I., et al., “Human Papillomavirus 16 E7 Protein is Associated with the Nuclear Matrix,” Proceedings of the National Academy of Sciences of the United States of America, Dec. 1991, vol. 88, pp. 11217-11221.
[cited by applicant]
Gregoriadis G., et al., “Vaccine Entrapment in Liposomes,” Methods, 1999, vol. 19, pp. 156-162.
[cited by applicant]
Gregoriadis G., “Immunological Adjuvants: A Role for Liposomes,” Immunology Today, The School of Pharmacy, University of London, 1990, vol. 11, No. 3, pp. 89-97.
[cited by applicant]
Hamley I.W., “Self-Assembly of Amphiphilic Peptides,” Soft Matter, 2011, vol. 7, pp. 4122-4138.
[cited by applicant]
Hartikka J., et al., “Vaxfectin (Registered), A Cationic Lipid-based Adjuvant For Protein-based Influenza Vaccines,” 2009, Vaccine, vol. 27, pp. 6399-6403.
[cited by applicant]
Hasegawa A., et al., “Nasal Immunization With Diphtheria Toxoid Conjugated-CD52 Core Peptide Induced Specific Antibody Production In Genital Tract Of Female Mice,” American Journal Of Reproductive Immunology, 2002, vol.…
[cited by applicant]
Hassan C., et al., “Naturally Processed Non-Canonical HLA-A 02:01 Presented Peptides,” The Journal of Biological Chemistry, 2015, vol. 290, No. 5, pp. 2593-2603, XP055497822.
[cited by applicant]
Helmby H., et al., “Interleukin-1 Plays A Major Role In The Development OfTh2-Mediated Immunity,” European Journal Of Immunology, WHILEY-VCH Verlag GmbH & Co., 2004, vol. 34, pp. 3674-3681.
[cited by applicant]
Holten-Anderson L., et al., “Combination of the Cationic Surfactant Dimethyl Dioctadecyl Ammonium Bromide and Synthetic Mycobacterial Cord Factor as an Efficient Adjuvant for Tuberculosis Subunit Vaccines,” Infection an…
[cited by applicant]
Hultner L., “In Activated Mast Cells, IL-1 Up-Regulates The Production Of Several Th2-Related Cytokines Including IL-9,” The American Association Of Immunologists, The Journal Of Immunology, 2000, vol. 164, pp. 5556-556…
[cited by applicant]
Immordino et al., “Stealth Liposomes: Review of the Basic Science, Rationale, and Clinical Applications, Existing and Potential,” International Journal of Nanomedicine, 2006, vol. 1, No. 03, pp. 297-315.
[cited by applicant]
Inaba K., et al., “Generation Of Large Numbers Of Dendritic Cells From Mouse Bone Marrow Cultures Supplemented With Granulocyte/Macrophage Colony-Stimulating Factor,” Journal Of Experimental Medicine, The Rockefeller Un…
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2009/040500, mailed Oct. 28, 2010, 6 Pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2013/045578, mailed Dec. 24, 2014, 7 Pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2013/061132, mailed Apr. 2, 2015, 10 Pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2017/055119, mailed Apr. 18, 2019, 16 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2009/040500, mailed Jun. 4, 2009, 7 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2013/045578, mailed Nov. 25, 2013, 9 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2013/061132, mailed Dec. 30, 2013, 12 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/055119, mailed Mar. 7, 2018, 23 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/060337, mailed Feb. 14, 2022, 7 Pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2008/057678, mailed Sep. 22, 2009, 5 Pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2012/054786, mailed Mar. 20, 2014, 6 Pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2016/061829, mailed May 24, 2018, 15 Pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2017/055348, mailed Apr. 18, 2019, 6 Pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2018/064060, mailed Jun. 18, 2020, 7 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2008/057678, mailed Apr. 20, 2009, 6 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2012/054786, mailed Nov. 15, 2012, 8 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/061829, mailed Feb. 24, 2017, 18 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/055348, mailed Jan. 5, 2018, 8 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2018/064060, mailed Apr. 30, 2019, 9 Pages.
[cited by applicant]
International Search Report for International Application No. PCT/US2008/057678, mailed Apr. 20, 2009, 3 Pages.
[cited by applicant]
International Search Report for International Application No. PCT/US2009/040500, mailed Jun. 4, 2009, 2 Pages.
[cited by applicant]
Ishida T., et al., “Defective Function Of Langerhans Cells In Tumor-Bearing Animals is the Result of Defective Maturation from Hemopoietic Progenitors,” The American Association Of Immunologists, The Journal Of Immunolo…
[cited by applicant]
Iwaoka S., et al., “Cationic Liposomes Induce Apoptosis Through p38 MAP-kinase-caspase-8-Bid Pathway in Macrophage-like RAW 264.7 Cells”, Journal of Leukocyte Biology, Jan. 2006, vol. 79, pp. 184-191, XP008117765.
[cited by applicant]
Jacob A., et al., “Convergence of Signaling Pathways on the Activation of ERK in B Cells,” The Journal of Biological Chemistry, The American Society for Biochemistry and Molecular Biology Incorporated, Jun. 28, 2002, vo…
[cited by applicant]
Jiao X., et al., “Modulation of Cellular Immune Response Against Hepatitis C Virus Nonstructural Protein 3 by Cationic Liposome Encapsulated DNA Immunization,” Hepatology, Feb. 2003, vol. 37, No. 2, pp. 452-460.
[cited by applicant]
Jisho: “Kojien,” Japanese Dictionary, Third Edition, Iwanami Shoten, 1983, 1 Page.
[cited by applicant]
Johnson G.L., et al., “Mitogen-activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases,” Science, Dec. 6, 2002, vol. 298, pp. 1911-1912.
[cited by applicant]
Jones C.A., et al., “Vaccination Strategies to Prevent Genital Herpes and Neonatal Herpes Simplex Virus (HSV) Disease,” Herpes, 2004, vol. 11, pp. 12-17.
[cited by applicant]
Joseph A., et al., “A New Intranasal Influenza Vaccine Based on a Novel Polycationic Lipid-Ceramide Carbamoyl-Spermine (CCS) I. Immunogenicity and Efficacy Studies in Mice,” Vaccine, 2006, vol. 24, pp. 3990-4006.
[cited by applicant]
Kabarowski J.H.S., et al., “Lysophospatidylcholine As A Ligand For The Immunoregulatory Receptor G2A,” Science, Department Of Microbiology, Immunology, And Molecular Genetics, Department Of Cancer Biology, Lerner Resear…
[cited by applicant]
Kahn J.O., et al., “Clinical and Immunologic Responses to Human Immunodeficiency Virus (HIV) Type 1SF2 GP120 Subunit Vaccine Combined with MF59 Adjuvant with or without Muramy1 Tripeptide Dipalmitoyl Phosphatidylethanol…
[cited by applicant]
Kanafani Z.A., et al., “Daptomycin: A Rapidly Bactericidal Lipopeptide for the Treatment of Gram-Positive Infections,” Experimental Review of Antibacterial Infections, Future Drugs Ltd, 2007, vol. 5, No. 2, pp. 177-184.
[cited by applicant]
Kantengwa S., et al., “Superoxide Anions Induce The Maturation of Human Dendritic Cells,” American Journal of Respiratory and Critical Care Medicine, Divisions of Pneumology and Thoracic Surgery, University Hospital, Ge…
[cited by applicant]
Kenter G.G., et al., “Vaccination Against Hpv-16 Oncoproteins for Vulvar Intraepithelial Neoplasia,” The New England Journal of Medicine, Nov. 5, 2009, vol. 361, pp. 1838-1847.
[cited by applicant]
Kim J.J., et al., “CD8 Positive T Cells Influence Antigen-Specific Immune Responses through the expression of Chemokines,” Journal Of Clinical Investigation, The American Society For Clinical Investigation, Inc., Sep. 1…
[cited by applicant]
Kogkopoulou O., et al., “Conditional Up-Regulation of IL-2 Production By p38 MAPK Inactivation Is Mediated By Increased ERKI/2 Activity,” Journal of Leukocyte Biology, May 2006, vol. 79, pp. 1052-1060.
[cited by applicant]
Kokkoli E., et al., “Self-assembly and Applications of Biomimetic and Bioactive Peptide-amphiphiles,” Soft Matter, 2006, vol. 2, pp. 1015-1024.
[cited by applicant]
Korsholm , “Unravelling the Adjuvant Mechanism of Cationic Liposomes,” Statens Serum Institute, Jun. 2006, pp. 15.00-15.30.
[cited by applicant]
Korsholm K.S., et al., “The Adjuvant Mechanism of Dimethyldioctadecyl-ammonium Liposomes,” Immunology, Jun. 2007, vol. 121, No. 2, pp. 216-226.
[cited by applicant]
Kranz L.M., et al., “Systemic RNA Delivery to Dendritic Cells Exploits Antiviral Defence for Cancer Immunotherapy,” Nature, Jun. 16, 2016, vol. 534, 16 Pages, DOI:10.1038/nature18300, XP055565453.
[cited by applicant]
Li S., et al., “Targeted Delivery of Antisense Oligodeoxynucleotide and Small Interference RNA Into Lung Cancer Cells,” Molecular Pharmaceutics, American Chemical Society, 2006, vol. 3, No. 5, pp. 579-588.
[cited by applicant]
Liang M.T., et al., “Encapsulation of Lipopeptides Within Liposomes: Effect of Number of Lipid Chains, Chain Length and Method of Liposome Preparation,” International Journal of Pharmaceutics, Elsevier B.V., 2005, vol. …
[cited by applicant]
Lodoen M.B., et al., “Natural Killer Cells as an Initial Defense Against Pathogens,” Current Opinion in Immunology, Elsevier Ltd, 2006, vol. 18, pp. 391-398.
[cited by applicant]
Lonez C., et al., “Cationic Liposomal Lipids: From Gene Carriers to Cell Signaling,” Progress in Lipid Research, 2008, vol. 47, pp. 340-347.
[cited by applicant]
Lucas W., et al., “Viral Capsids and Envelopes: Structure and Function,” Encyclopedia of Life Sciences (ELS), John Wiley & Sons, 2010, pp. 1-7.
[cited by applicant]
Mackay C.R., “Chemokines: Immunology's High Impact Factors,” Nature Immunology, Feb. 2001, vol. 2, No. 2, pp. 95-101.
[cited by applicant]
Mansour M., et al., “Therapy Of Established B16-f10 Melanoma Tumors By A Single Vaccination Of Ctl/t Helper Peptides In Vaccimax,” Journal of Translational Medicine, 2007, vol. 5, No. 20, 8 Pages.
[cited by applicant]
Melief C.J.M., et al., “Effective Therapeutic Anticancer Vaccines Based on Precision Guiding of Cytolytic T Lymphocytes,” Blackwell Munksgaard, Immunological Reviews, 2002, vol. 188, pp. 177-182.
[cited by applicant]
Minutello M., et al., “Safety And Immunogenicity Of An Inactivated Subunit Influenza Virus Vaccine Combined With MF59 Adjuvant Emulsion In Elderly Subjects,” Immunized For Three Consecutive Influenza Seasons, Vaccine, E…
[cited by applicant]
Moingeon P., et al., “Towards the Rational Design of Th1 Adjuvants,” Vaccine, Elsevier Science Limited, 2001, vol. 19, pp. 4363-4372.
[cited by applicant]
Non Final Office Action for Counterpart mailed Mar. 5, 2020 for U.S. Appl. No. 16/532,728, 12 Pages.
[cited by applicant]
Non Final Office Action mailed Apr. 29, 2022 for U.S. Appl. No. 14/531,469, 12 Pages.
[cited by applicant]
Non-Final Office Action from Counterpart U.S. Appl. No. 15/775,680, mailed Apr. 1, 2020, 14 Pages.
[cited by applicant]
Notification of Reason of Rejection of Japanese Application No. JP2017218514, mailed Aug. 21, 2018, 13 pages.
[cited by applicant]
Office Action for Canadian Application No. 2885741, dated May 10, 2022, 03 pages.
[cited by applicant]
Office Action for European Application No. 08799629.4, mailed Aug. 7, 2012, 4 Pages.
[cited by applicant]
Office Action for European Application No. 08799629.4, mailed Jan. 10, 2014, 3 Pages.
[cited by applicant]
Office Action for European Application No. 08799629.4, mailed May 17, 2010, 1 Page.
[cited by applicant]
Office Action for European Application No. 08799629.4, mailed Apr. 26, 2011, 3 Pages.
[cited by applicant]
Office Action for European Application No. 09733034.4, mailed Apr. 16, 2015, 5 Pages.
[cited by applicant]
Office Action for European Application No. 09733034.4, mailed Nov. 18, 2016, 4 Pages.
[cited by applicant]
Office Action for European Application No. 12831495.2, mailed Dec. 1, 2016, 4 Pages.
[cited by applicant]
Office Action for European Application No. 12831495.2, mailed Jun. 6, 2016, 5 Pages.
[cited by applicant]
Office Action for European Application No. 12831495.2, mailed May 11, 2017, 4 Pages.
[cited by applicant]
Office Action for European Application No. 13804165.2, mailed Mar. 2, 2018, 3 Pages.
[cited by applicant]
Office Action for European Application No. 13804165.2, mailed Jul. 5, 2017, 4 Pages.
[cited by applicant]
Office Action for European Application No. 13804165.2, mailed May 17, 2018, 3 Pages.
[cited by applicant]
Office Action for European Application No. 13804165.2, mailed Sep. 22, 2016, 3 Pages.
[cited by applicant]
Office Action for European Application No. 13804165.2, mailed Aug. 23, 2018, 3 Pages.
[cited by applicant]
Office Action for European Application No. 13839199.0, mailed Nov. 13, 2017, 4 Pages.
[cited by applicant]
Office Action for European Application No. 13839199.0, mailed Nov. 21, 2016, 4 Pages.
[cited by applicant]
Office Action for European Application No. 13839199.0, mailed Jul. 30, 2018, 4 Pages.
[cited by applicant]
Office Action for European Application No. 16865201.4, mailed on Jul. 16, 2020, 5 Pages.
[cited by applicant]
Office Action for European Application No. 19203293.6, mailed Feb. 19, 2021,4 Pages.
[cited by applicant]
Office Action for European Application No. 19203293.6, mailed Dec. 22, 2021, 4 Pages.
[cited by applicant]
Office Action for Taiwanese Application No. TW101133392, with English Translation, mailed Jul. 17, 2017, 05 pages.
[cited by applicant]
Office Action from Corresponding Indian Application No. 7544/DELNP/2010, dated Jun. 22, 2017, 10 Pages.
[cited by applicant]
Office Action from Counterpart Brazilian Patent Application. No. PI0910464-0, dated Nov. 6, 2018, and a Brief Summary in English, 5 pages.
[cited by applicant]
Office Action of European Application No. 12831495.2, mailed Nov. 17, 2015, 5 pages.
[cited by applicant]
Office Action of Taiwanese Application No. 101133392, dated May 16, 2016, along with an English translation of the Search Report, 8 pages.
[cited by applicant]
Okada N., et al., “Effects of Lipofectin-Antigen Complexes on Major Histocompatibility Complex Class I-Restricted Antigen Presentation Pathway in Murine Dendritic Cells and on Dendritic Cell Maturation,” Biochimica et B…
[cited by applicant]
Oliveira L.M.F.D., et al., “Design of Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine,” PLoS ONE, 2015, vol. 10, No. 9: e0138686, 13 Pages.
[cited by applicant]
Padron-Regalado E., “Vaccine for SARS-CoV-2: Lessons from Other Coronavirus Strains,” Infectious Diseases and Therapeutics, 2020, vol. 9, pp. 255-274.
[cited by applicant]
Pialoux G.D., et al., “Lipopeptides Induce Cell-Mediated Anti-HIV Immune Responses In Seronegative Volunteers,” Lippincott Williams & Wilkins, Inc., Official Journal Of The International Of AIDS, Jul. 6, 2001, vol. 15, …
[cited by applicant]
Pierre Y., et al., “Liposome-Mediated DNA Immunisation via the Subcutaneous Route,” Journal of Drug Targeting, Taylor & Francis Ltd, 2003, vol. 11, No. 8-10, pp. 555-563.
[cited by applicant]
Cited By (1)